Darbepoetin alfa
- Generic Name
- Darbepoetin alfa
- Brand Names
- Aranesp
- Drug Type
- Biotech
- CAS Number
- 209810-58-2
- Unique Ingredient Identifier
- 15UQ94PT4P
- Background
Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
- Indication
For the treatment of anemia (from renal transplants or certain HIV treatment)
- Associated Conditions
- Anemia
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy
Phase 2
Terminated
- Conditions
- AnemiaNeoplasmsCancer
- Interventions
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2013-07-19
- Target Recruit Count
- 235
- Registration Number
- NCT00386152
Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer
Phase 2
Terminated
- Conditions
- Prostatic NeoplasmsAnemia
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 140
- Registration Number
- NCT00381836
- Locations
- 🇩🇰
Department of Urology, Aarhus University Hospital, Aarhus, Denmark
COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT00377481
STAAR-2 Clinical Study
Phase 4
Completed
- Conditions
- Chronic Kidney DiseaseChronic Renal InsufficiencyKidney DiseasePre-dialysisPre-ESRD
- Interventions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2010-03-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 618
- Registration Number
- NCT00368901
STAAR-3 Clinical Study
Phase 4
Completed
- Conditions
- Chronic Kidney DiseaseChronic Renal InsufficiencyKidney DiseasePre-dialysisPre-ESRD
- Interventions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2010-02-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 443
- Registration Number
- NCT00369733
STAAR-1 Clinical Study
Phase 4
Completed
- Conditions
- Chronic Kidney DiseaseChronic Renal InsufficiencyKidney DiseasePre-dialysisPre-ESRD
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2009-10-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2000
- Registration Number
- NCT00369772
STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) Patients
Phase 3
Terminated
- Conditions
- AnemiaChronic Kidney Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-08-16
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 51
- Registration Number
- NCT00364845
A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor
Phase 2
Completed
- Conditions
- Anemia
- First Posted Date
- 2006-08-03
- Last Posted Date
- 2012-08-31
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT00359840
- Locations
- 🇯🇵
Tokai region, Aichi, Japan
🇯🇵Kanto region, Tochigi, Saitama, Tokyo, Kanagawa, Japan
🇯🇵Hokuriku region, Niigata, Ishikawa, Japan
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Phase 3
Completed
- Conditions
- Congestive Heart FailureVentricular DysfunctionHeart FailureAnemiaCardiovascular Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-07-31
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2278
- Registration Number
- NCT00358215
- Locations
- 🇬🇧
Research Site, York, United Kingdom
Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation
Not Applicable
Completed
- Conditions
- Hematologic Malignancies
- First Posted Date
- 2006-07-21
- Last Posted Date
- 2009-03-13
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 31
- Registration Number
- NCT00355407
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath